ASCO 2022 | Next steps for belzutifan for Von Hippel-Lindau syndrome

Ramaprasad Srinivasan, MD, PhD, National Cancer Institute, Bethesda, MD, discusses the potential of belzutifan for patients with Von Hippel-Lindau syndrome, and the next steps in investigating how this drug could benefit these patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.